Hanseul Oh

TL;DR: The in vitro antiviral properties of heparin and other closely related polysaccharides are evaluated to assess the relevance of he parin-related GAGs and other sulfated poly Saccharina japonica, chemo-enzymatically synthesized trisulfated (TriS) hepar in, and unfractionated USP-heparin as part of the pharmacopeia of potential therapeutics that target SARS-CoV-2.

TL;DR: In this article, human monoclonal antibodies targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient.

TL;DR: It is shown that SARS-CoV-2 causes a coronavirus disease 2019 (COVID-19)-like disease in macaques and a significant loss of total lymphocytes during infection, which were restored over time.

TL;DR: In this article, a previously unknown subunit vaccine comprising the receptor binding domain (RBD) of the spike protein fused with the tetanus toxoid epitope P2 was developed and tested in rodents and nonhuman primates (NHPs).

TL;DR: X-19-vaccinated nonhuman primates seroconverted rapidly and exhibited a detectable neutralizing antibody response as well as multifunctional CD4+ and CD8+ T cell responses as discussed by the authors.